BIRC5 and laryngeal carcinoma: The CCK-8 assay data showed blocking survivin expression by transfected siRNA targeting survivin in hypoxic laryngeal carcinoma cells could strikingly elevate sensitivity to doxorubicin, gemcitabine, paclitaxel, cisplatin, and 5-FU under hypoxic conditions (Tables 1 and 2, P < 0.05).